Dr. Kopelman's research primarily focuses on the effects of certain medical treatments and conditions on patient well-being, particularly regarding mental health, pregnancy, and cancer. For example, he studies how intravenous ketamine can quickly relieve symptoms of treatment-resistant depression by inducing significant brain changes. He also examines the safety of pregnancy for women living with HIV and how various maternal factors affect fetal growth. Additionally, Dr. Kopelman investigates the use of therapy animals in enhancing the quality of life for patients undergoing cancer treatment and the psychological impact on medical staff.
Key findings
In a study on treatment-resistant depression, patients who received ketamine showed significant brain structure changes within 24 hours, correlating with improved depression scores.
In therapy animal programs for surgical oncology patients, participants reported a better quality of life and increased energy, while staff experienced reduced burnout.
For babies born to HIV-positive mothers, those with a CD4 count below 200 were nearly 9 times more likely to experience fetal growth restriction compared to those with higher counts.
Research on third-trimester deliveries found that delivering babies right at or after 39 weeks reduced neonatal death risks for most newborns.
Among HIV-positive women on protease inhibitor therapy, 29% experienced fetal growth restriction, compared to 15.3% in those not on such therapy.
Frequently asked questions
Does Dr. Kopelman study depression treatments?
Yes, he specifically investigates the effects of intravenous ketamine on treatment-resistant depression.
What are the outcomes of therapy animals in oncology settings?
His research shows that therapy animals improve quality of life for surgery patients and enhance job satisfaction for healthcare staff.
Is Dr. Kopelman’s work relevant to pregnant women with HIV?
Absolutely, he has published several studies on how maternal HIV affects fetal growth and pregnancy outcomes.
What factors does Dr. Kopelman study related to fetal health?
He explores how maternal health factors, such as HIV status and blood pressure, impact fetal growth and developmental risks.
Does Dr. Kopelman work with any surgical conditions?
Yes, he has researched surgical techniques and outcomes for conditions like brachymetatarsia and uveal melanoma.
Publications in plain English
Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression.
2023
Translational psychiatry
Kopelman J, Keller TA, Panny B, Griffo A, Degutis M +8 more
Plain English This study examined how intravenous ketamine affects brain changes related to depression in 98 adults who had not responded to other antidepressant treatments. Researchers found that those who received ketamine showed greater changes in brain structure within 24 hours, which correlated with improvements in their depression scores; specifically, a significant decrease in markers of neuroplasticity was linked to better outcomes in several brain areas. This research is important because it helps us understand how ketamine may quickly alleviate depression symptoms by triggering brain changes.
Who this helps: Patients with treatment-resistant depression.
Animal-Facilitated Therapy Program: Outcomes from Caring Canines, a Program for Patients and Staff on an Inpatient Surgical Oncology Unit.
2018
Clinical journal of oncology nursing
Ginex P, Montefusco M, Zecco G, Trocchia Mattessich N, Burns J +3 more
Plain English This study looked at how having therapy animals in a surgical oncology unit affects both patients and staff. It found that patients reported better quality of life and increased energy after participating in the program, while staff experienced high job satisfaction and low feelings of burnout. This matters because it shows that therapy animals can positively impact the well-being of both patients undergoing treatment and the healthcare workers caring for them.
Who this helps: This helps patients in surgical oncology and the healthcare professionals who support them.
Third trimester perinatal mortality associated with immediate delivery versus expectant management according to birthweight category.
2017
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
Contag S, Brown C, Kopelman J, Goetzinger K
Plain English This study looked at the outcomes of babies born during the third trimester, comparing immediate delivery to waiting for birth in a low-risk group of mothers, based on the babies' birthweight. Researchers analyzed data from nearly 5 million births and found that for most babies, delivering right at or after 39 weeks reduced the risk of neonatal death compared to waiting. However, for very large babies (over the 95th percentile in weight), waiting was not beneficial after 37 weeks, as immediate delivery had a higher risk of death at 36 weeks but a lower risk at 37 weeks onwards.
Who this helps: This information is important for doctors and healthcare providers in making decisions about delivery for expecting mothers and their babies.
First-trimester angiopoietin-2: relationships with maternal and placental characteristics.
2010
American journal of perinatology
Baschat AA, Kasdaglis T, Aberdeen G, Turan O, Kopelman J +4 more
Plain English This study focused on a substance called angiopoietin-2 (Ang-2) in pregnant women during the first trimester to see how its levels relate to various factors about the mother and the placenta. In 111 women, Ang-2 levels ranged from 0.6 to 10.9 ng/mL and were found to be lower in women with higher body mass index (BMI) and mean arterial pressure (MAP), indicating a connection between Ang-2 and maternal health issues. Understanding these relationships is important because they can help identify risks for abnormal placental development, which can affect pregnancy outcomes.
Who this helps: This helps pregnant women and healthcare providers by offering insights into placental health.
Placental growth factor in the first trimester: relationship with maternal factors and placental Doppler studies.
2010
Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
Kasdaglis T, Aberdeen G, Turan O, Kopelman J, Atlas R +4 more
Plain English This study looked at placental growth factor (PlGF) in pregnant women during their first trimester to understand how it relates to various health factors of both the mother and the placenta. They found that PlGF levels, which varied from 1.0 to 176.1 pg/mL, increased with the progression of pregnancy but were lower in women with specific blood flow patterns in their uterine arteries. Understanding PlGF can help identify pregnancies at risk for complications early on, which is important for the health of both mother and baby.
Who this helps: Patients and healthcare providers managing early pregnancy risks.
Plain English This study looked at how maternal HIV disease affects fetal growth during pregnancy. Researchers found that pregnant women with a CD4 count below 200 in their first trimester were nearly nine times more likely to have fetal growth restrictions compared to those with higher counts. Additionally, factors like maternal age and smoking also negatively impacted fetal growth.
Who this helps: This information is valuable for doctors treating HIV-positive pregnant women.
Chronic hypoxia differentially increases glutathione content and gamma-glutamyl cysteine synthetase expression in fetal guinea pig organs.
2008
Early human development
Oh C, Dong Y, Harman C, Mighty HE, Kopelman J +1 more
Plain English Researchers studied how low oxygen levels (hypoxia) during pregnancy affect the levels of glutathione, a natural antioxidant, in the organs of fetal guinea pigs. They found that when pregnant guinea pigs experienced hypoxia, the glutathione levels in the fetal liver increased by 121%, while the lungs and kidneys did not show similar changes. This is important because it shows that the fetal liver adapts specifically to low oxygen conditions, which may help protect against damage caused by lack of oxygen.
Who this helps: This helps patients, particularly those at risk for complications during pregnancy due to low oxygen levels.
Protease inhibitor therapy and fetal growth potential in HIV-positive women.
2008
American journal of perinatology
Iqbal S, Kriebs J, Harman C, Gungor S, Alger L +4 more
Plain English In this study, researchers looked at whether protease inhibitor (PI) therapy for HIV affects fetal growth in pregnant women. They found that among 191 women studied, 29% of those on PIs experienced fetal growth restriction (FGR), compared to 15.3% of those not on PIs. Importantly, a mother's CD4 count was the biggest factor affecting the risk of FGR, with smoking also significantly contributing to the risk.
Who this helps: This information helps doctors and healthcare providers caring for HIV-positive pregnant women.
Plain English This study looked at a specific type of laser called the Erbium: YAG laser and how it improves skin treatments around the eyes. The researchers found that this laser causes less damage to the skin compared to older methods, resulting in faster healing and fewer side effects like redness and scarring. This is important because it offers a safer option for people looking to reduce wrinkles and improve the appearance of the skin around their eyes.
Who this helps: Patients seeking cosmetic improvements around their eyes.
The acquisition of herpes simplex virus during pregnancy.
1997
The New England journal of medicine
Brown ZA, Selke S, Zeh J, Kopelman J, Maslow A +5 more
Plain English This study looked at how often pregnant women get infected with the herpes simplex virus (HSV) and the effects of these infections on pregnancy outcomes. Out of over 7,000 women, 94 ended up with a herpes infection during their pregnancy, and 30% of these infections happened in the third trimester. The research found that if women became infected before labor, it did not increase the risk of problems for the baby, but infections that occurred just before birth were linked to serious issues, including one infant death.
Who this helps: This research benefits pregnant women and their healthcare providers by highlighting the risks of herpes infections during pregnancy.
Alternative autogenous bone graft donor sites in brachymetatarsia reconstruction: a review of the literature with clinical presentations.
1991
The Journal of foot surgery
Kashuk KB, Hanft JR, Schabler JA, Kopelman J
Plain English This study reviews different surgical approaches for treating a condition called brachymetatarsia, where one or more toes are shorter than normal. The authors looked at where doctors can take bone grafts from a patient’s foot to help reconstruct the toes and shared three specific case examples. Understanding these donor sites matters because it can lead to better surgical outcomes for patients with this condition.
Who this helps: This helps patients with brachymetatarsia needing surgery to correct their toe length.
Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.
1988
The Laryngoscope
Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY
Plain English This study looked at the impact of high-dose cisplatin chemotherapy on the hearing of patients with advanced cancer who initially had normal hearing. Researchers found that after just one or two doses, every patient experienced severe hearing loss, particularly in the high frequencies (9,000 Hz and above), with a moderate loss of hearing (40 to 60 dB) noted at lower high frequencies (between 3,000 and 8,000 Hz). All participants also reported ringing in the ears and issues understanding speech in noisy environments, highlighting the significant risks of using this treatment.
Who this helps: This helps patients undergoing high-dose cisplatin therapy and their doctors by informing them about the risks to hearing.
Plain English This study looked at three rare cases of a type of eye cancer called uveal melanoma that spread outside the eye and formed a mass in the orbit (the area around the eye). Out of these cases, two occurred in eyes that were already blind, and after surgery and radiation treatment, two of the three patients sadly died from cancer spreading to other parts of their body. This highlights the need for regular monitoring of tumors, especially in blind eyes, to catch any issues early on.
Who this helps: This helps patients with uveal melanoma and doctors who treat them.
Plain English This study looked at 22 patients with eyelid spasms, either benign essential blepharospasm or hemifacial spasm, who were treated with botulinum toxin injections in the eyelids and eyebrows. After receiving a standard dose of 12.5 units on each side, all patients experienced reduced spasms and noticeable muscle weakness, although the spasms sometimes returned even when the muscle remained weak. The relief from symptoms lasted around six to 12 weeks, and side effects were minimal.
Who this helps: This benefits patients with eyelid spasms seeking effective treatment.
Four-year experience with argon laser trabecular surgery in uncontrolled open-angle glaucoma.
1983
Ophthalmology
Schwartz AL, Kopelman J
Plain English This study looked at how effective a type of eye surgery called argon laser trabecular surgery is for patients with uncontrolled open-angle glaucoma. Out of 82 eyes treated, 77% showed successful results, with an average pressure drop in the eye from 24.2 mmHg to 14.5 mmHg over two months. The surgery is especially helpful for older patients or those with certain types of glaucoma and is considered a good option for those who haven't had success with medication alone.
Who this helps: Patients with uncontrolled open-angle glaucoma.
Plain English This study looked at a rare, non-cancerous eye tumor called retinocytoma in five children, finding that these tumors had a characteristic appearance and did not show signs of aggressive growth. All children were healthy and alive after being treated by removing the tumor, with follow-ups between three and 14 years later. Recognizing retinocytoma as a benign variant of retinoblastoma is important because it helps clarify the genetic risks associated with these tumors.
Who this helps: Patients with benign eye tumors and their doctors.